Company profile: Autolus Therapeutics
1.1 - Company Overview
Company description
- Provider of next-generation programmed T cell therapies for cancer, leveraging T-cell programming and manufacturing technology. Pipeline includes CAR T products such as obe-cel (obecabtagene autoleucel) for adult ALL; AUTO1/22 for pediatric ALL; AUTO4 (TRBC1) and AUTO5 (TRBC2) for peripheral T-cell lymphoma; AUTO6NG (GD2) for neuroblastoma and other solid tumors; and AUTO8 (BCMA/CD19) for multiple myeloma.
Products and services
- Obe-cel (obecabtagene autoleucel): A custom-engineered CD19 CAR T therapy for adult ALL, architected to minimize excessive T-cell activation and reduce toxicity
- AUTO8: A next-generation CAR T product for multiple myeloma, combining BCMA and CD19 targeting to enhance target-cell killing and durability against disease persistence
- AUTO1/22: A dual-targeting CAR T therapy for pediatric ALL, integrating CD19 and CD22 CARs to reduce antigen-negative relapses
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Autolus Therapeutics
MultiCell Technologies
HQ: United States
Website
- Description: Provider of biopharmaceutical solutions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MultiCell Technologies company profile →
Obsidian Therapeutics
HQ: United States
Website
- Description: Provider of next-generation cell and gene therapies to extend adoptive immunotherapy, offering the cytoDRiVE platform that controls protein function using drug-responsive domains and FDA-approved small molecules, and OBX-115, a TIL cell therapy engineered to produce membrane-bound IL15 to eliminate co-administered high-dose IL2 in advanced or metastatic melanoma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Obsidian Therapeutics company profile →
Atlab Pharma
HQ: France
Website
- Description: Provider of antibody-targeted anti-cancer drugs and radioimmunotherapy, developing monoclonal antibody-radioisotope conjugates to deliver tumor-specific radiation to cancer cells wherever they have disseminated in the body.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Atlab Pharma company profile →
Y-mAbs Therapeutics
HQ: United States
Website
- Description: Provider of innovative cancer treatments and support services, including FDA-approved DANYELZA (naxitamab-gqgk) for relapsed or refractory high-risk neuroblastoma in bone or bone marrow; clinical trials for investigational therapies (naxitamab, omburtamab, GD2-SADA); expanded access programs; Y-mAbs Connect for access, insurance and financial support; and patient and family resources.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Y-mAbs Therapeutics company profile →
Neutec Pharma
HQ: United Kingdom
Website
- Description: Provider of biopharmaceuticals developing and manufacturing genetically recombinant antibody therapies and platform technologies. Products include Mycograb targeting heat shock protein 90 for systemic candidiasis; Aurograb targeting Staphylococcus aureus, including MRSA and VISA, used with vancomycin for MRSA; and FABTEC, a platform for identifying new therapeutic antibody fragments.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Neutec Pharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Autolus Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Autolus Therapeutics
2.2 - Growth funds investing in similar companies to Autolus Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Autolus Therapeutics
4.2 - Public trading comparable groups for Autolus Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →